吸入TLR9激动剂AZD1419治疗哮喘的2a期随机对照试验
这项2a期随机双盲安慰剂对照试验纳入有嗜酸性粒细胞升高史的成人哮喘患者,评估吸入TLR9激动剂AZD1419的疗效与安全性。AZD1419诱导了Th1型IFN反应并持续降低2型炎症标志物,但在至哮喘失控时间等主要和次要终点上与安慰剂无统计学显著差异。AZD1419安全耐受良好,FeNO早期升高可预测63%患者的哮喘失控。
要点
- AZD1419诱导Th1型IFN反应并持续降低2型炎症标志物
- 至哮喘失控时间等终点与安慰剂无统计学显著差异
- AZD1419安全耐受良好,无死亡或相关严重不良事件
核心结论
- AZD1419安全且耐受良好,但尽管降低了2型炎症标志物,并未改善哮喘控制。
- 结果提示基于FeNO的加速降阶梯方案对控制良好的哮喘患者可行。
研究设计与样本
- 2a期随机双盲安慰剂对照试验,纳入有嗜酸性粒细胞升高史(>250 cells/μl)的成人哮喘患者。
- 患者按1:1随机接受13次每周一次的吸入AZD1419(1、4或8 mg;n=40)或安慰剂(n=41)。
- 吸入糖皮质激素和长效β2受体激动剂逐渐减量后停用,AZD1419最后四剂无维持治疗,随后40周观察。
- 主要终点为至哮喘失控(LOC)时间。
主要发现
- AZD1419诱导Th1型IFN反应,并持续降低2型炎症标志物。
- AZD1419与安慰剂在至LOC时间、LOC患者比例、ACQ-5变化、急性发作、缓解药物使用、FEV1、PEF或FeNO上均无统计学显著差异。
- 63%患者的LOC由FeNO早期升高预测。
- 尽管停用维持治疗,24例患者完成研究且无LOC(AZD1419组11例,安慰剂组13例)。
- 不良事件组间均衡,无死亡或判定与AZD1419因果相关的严重不良事件。
临床怎么用
- AZD1419虽降低2型炎症标志物但未改善哮喘控制,不支持其用于哮喘控制改善。
- FeNO早期升高可预测63%患者的哮喘失控,提示FeNO可用于监测。
- 基于FeNO的加速降阶梯方案对控制良好的哮喘患者可能可行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: To examine the potential of TLR9 (Toll-like receptor 9) activation to modulate the type 2 immune response in asthma.Objectives: To evaluate efficacy and safety of AZD1419, an inhaled TLR9 agonist, in a phase 2a, randomized, double-blind trial.Methods: Adult patients with asthma with a history of elevated eosinophils (>250 cells/μl) were randomized 1:1 to receive 13 once-weekly doses of inhaled AZD1419 (1, 4, or 8 mg; n = 40) or placebo (n = 41). Inhaled corticosteroids and long-acting β2-agonist were tapered down and then discontinued. The last four doses of AZD1419 were given without maintenance medication, followed by a 40-week observation period. Primary endpoint was time to loss of asthma control (LOC).Measurements and Main Results: AZD1419 induced a T-helper cell type 1-type IFN response with a sustained reduction in markers of type 2 inflammation. However, there were no statistically significant differences between AZD1419 and placebo for time to LOC, proportion of patients with LOC, changes in Asthma Control Questionnaire-five-item version, exacerbations, reliever use, FEV1, peak expiratory flow, or fractional exhaled nitric oxide (FeNO). LOC was predicted by an early rise in FeNO in 63% of patients. Despite withdrawal of maintenance treatment, 24 patients completed the study without LOC; AZD1419 n = 11, placebo n = 13. Adverse events were balanced across groups, with no deaths or serious adverse events judged as causally related to AZD1419.Conclusions: AZD1419 was safe and well tolerated but did not lead to improved asthma control, despite reducing markers of type 2 inflammation. Results suggest that a novel accelerated step-down approach based on FeNO is possible for patients with well-controlled asthma.
引用
- Psallidas I, Backer V, Kuna P, et al. A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma. Am J Respir Crit Care Med. 2021. PMID: 32809843. doi:10.1164/rccm.202001-0133OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。